Safinamide mesylate
CAS: 202825-46-5
Ref. 3D-FS101887
5g | 186.00 € | ||
10g | 310.00 € | ||
25g | 485.00 € | ||
50g | 740.00 € | ||
100g | 1,159.00 € |
Product Information
- (S)-2-[[4-[(3-Fluorobenzyl)oxy]benzyl]amino]propanamide methanesulfonate
- EMD 1195686 mesylate
- FCE-28073(R-isomer)
- Fce-26743
- Nw-1015
- N~2~-{4-[(3-fluorobenzyl)oxy]benzyl}-D-alaninamide methanesulfonate
- Pnu-151774E
- Propanamide, 2-[[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]amino]-, (2S)-, methanesulfonate (1:1)
- Propanamide, 2-[[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]amino]-, (2S)-, monomethanesulfonate
- Propanamide, 2-[[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]amino]-, (S)-, monomethanesulfonate
- See more synonyms
- Safinamide mesilate
- Safinamide methanesulfonate
- Xadago
Safinamide mesylate is a drug that has been approved for the treatment of Parkinson's disease in Japan. It is an inhibitor of monoamine oxidase-B (MAO-B) and dopamine beta-hydroxylase, which are enzymes that break down dopamine. Safinamide mesylate has a chemical structure that reacts with hydrochloric acid to produce hydrogen gas and an acid formation. The drug also inhibits the conversion of dopamine to dihydroxyphenylacetic acid (DOPAC), which causes an accumulation of dopamine in the brain. Safinamide mesylate is metabolized by hydroxylation, deamination, and oxidation; its metabolites are excreted through urine. Pharmacokinetic studies have shown that safinamide mesylate has linear pharmacokinetics after intravenous injection or oral administration. Analysis by high performance liquid chromatography-tandem mass spectrometry (LC-MS/MS) has revealed the presence of two metabolites
Chemical properties
Technical inquiry about: 3D-FS101887 Safinamide mesylate
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.